Working... Menu

Bromfenac Versus Dexamethasone After Cataract Surgery (BVD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03317847
Recruitment Status : Active, not recruiting
First Posted : October 23, 2017
Last Update Posted : June 18, 2018
Information provided by (Responsible Party):
Arcispedale Santa Maria Nuova-IRCCS

Brief Summary:
The aim of the study is to compare bromfenac to dexamethasone eye drops to control inflammation after cataract surgery. Inflammation in the anterior chamber of the eye will be measured by a Laser Flare Photometer (LFP).

Condition or disease Intervention/treatment Phase
Inflammation Eye Drug: Bromfenac 0.09 % Ophthalmic Solution Drug: Dexamethasone 0.1% ophthalmic suspension Phase 4

Detailed Description:

The BVD study is a phase IV, single centre, randomized, active-control, parallel design, open-label trial comparing Bromfenac ophthalmic solution 0.1% and Dexamethasone ophthalmic suspension 0.1% in patients older than 60 years after unilateral cataract surgery.

A total of 76 patients (38 for each arm) will be included in this study. Patients will be selected among subjects who underwent cataract surgery the day before the study enrolment. Enrolment will take place at the participating hospital.

Eligible subjects will be sequentially assigned, according to a computer-generated randomization list (1:1), to one of the following treatment groups:

  • Experimental Arm: Bromfenac ophthalmic solution 0.1% eye drops, 2 times per day in the study eye for two weeks;
  • Standard Arm: Dexamethasone ophthalmic suspension 0.1% eye drops, 4 times per day in the study eye for the first week and 2 times per day in the study eye for the second week.

Each group must start the drops the day after cataract surgery, for two weeks.

The first post-operative clinical evaluation is planned the day after cataract surgery. The following procedures will be performed on the study eye and data will be collected during this first clinical encounter:

  • Eye Drops Usage training
  • Concomitant medications
  • Best-corrected Visual Acuity
  • Laser Flare Photometry
  • Slit lamp biomicroscopy
  • Intracular pressure (IOP) with pneumotonometer,
  • Dilated fundus ophthalmoscopy
  • Ocular Comfort Grading Assessment

At least six post-operative follow-up visits are planned after 3, 7, 9, 11, 14 days (±1 day) and 30 days (±3 days) from cataract extraction plus possible adjunctive controls if problems/complications will occur. The following procedures will be performed on the study eye and data will be collected during all clinical encounters:

  • Compliance with study medication
  • Concomitant medications
  • Best-corrected Visual Acuity (only day 7, 14, 30)
  • Laser Flare Photometry
  • Optical Coherence Tomography testing (only day 30)
  • Slit lamp biomicroscopy (only day 7, 14 and 30)
  • IOP with pneumotonometer (only day 7, 14 and 30)
  • Dilated fundus ophthalmoscopy (only day 30)
  • Ocular Comfort Grading Assessment (only day 7, 14 and 30)
  • Adverse events

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 76 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Bromfenac 0.09% Versus Dexamethasone 0.1% Ophthalmic Solutions to Reduce Inflammation After Cataract Surgery
Actual Study Start Date : October 16, 2017
Actual Primary Completion Date : June 14, 2018
Estimated Study Completion Date : December 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Cataract

Arm Intervention/treatment
Experimental: Bromfenac
Patients randomized to this arm will receive Bromfenac 0.09 % Ophthalmic Solution BID for 2 weeks
Drug: Bromfenac 0.09 % Ophthalmic Solution
Patients will self-administer 1 drop of Bromfenac twice daily to the affected eye beginning 1 day after cataract surgery and then continuing through the first 14 days of the postoperative period.
Other Name: Yellox

Active Comparator: Dexamethasone
Patients randomized to this arm will receive Dexamethasone 0.1 % Ophthalmic Suspension QID for one week and BID for the following week
Drug: Dexamethasone 0.1% ophthalmic suspension
Patients will self-administer 1 drop of Dexamethasone to the study eye beginning 1 day after cataract surgery 4 times daily during the first postoperative week and 2 times daily in the second postoperative week.

Primary Outcome Measures :
  1. Flare to baseline [ Time Frame: Within one month ]
    Time needed to revert the postoperative flare (measured by laser flare meter in the anterior chamber of the eye) to the preoperative or lower level.

  2. Flare at day 14 [ Time Frame: 14 days ]
    Proportion of patients who will have a postoperative flare at day 14 equal or inferior to the preoperative value in the two groups

Secondary Outcome Measures :
  1. Best Corrected Visual Acuity (BCVA) [ Time Frame: 14 days ]
    Proportion of subjects with BCVA equal to 10/10 at day 14 in the two groups

  2. Macular thickness at optical coherence tomography (OCT) [ Time Frame: 1 month ]
    Proportion of patients with central macular thickness greater than 300 microns at day 30 in the two groups

  3. Ocular Comfort Grading Assessment (OCGA) [ Time Frame: 14 days ]
    Safety endpoint: proportion of patients with no ocular discomfort at day 14. Ocular discomfort will be assessed by the OCGA scale. The OCGA measures 7 ocular symptoms (eye pain, tearing, itching, foreign body sensation, photophobia, eye discharge, haziness); at visits, patients will assess the severity by grading each symptom as none (0), mild (1), moderate (2), or severe (3)

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   60 Years to 90 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  1. Age > 60 year old.
  2. Uneventful cataract surgery. Surgical procedure, as described in the patients chart, should be free of any form of intraoperative complication that may increase postoperative inflammation.
  3. Availability of relevant ocular history, including: Best Corrected Visual Acuity testing, Laser Flare Photometry, Optical Coherence Tomography, slit lamp biomicroscopy, intraocular pressure (with pneumotonometer), dilated fundus ophthalmoscopy.
  4. Ability and willing to follow all instructions and attend all study visits
  5. Ability to self-administer study drug (or have a caregiver available to instill all doses of study drug)
  6. Ability and willing to provide informed consent for this study protocol.
  7. No ocular, topical, systemic, or inhaled NSAIDs or ocular, topical, or systemic gentamicin, or cyclosporine ophthalmic emulsion within 1 week of investigational product initiation or throughout the duration of the study;
  8. No topical, inhaled, or systemic corticosteroids within 15 days or depot corticosteroids within 45 days of the investigational product initiation or or throughout the duration of the study;
  9. No oral tamsulosin at any time during the clinical trial;
  10. Any ocular, topical, or systemic medication that could interfere with normal lacrimation, wound healing, the investigational product, or the interpretation of clinical trial results.
  11. For women, the menopausal state is assumed.


  1. Ocular exclusion criteria:

    1. history of ocular inflammation or trauma;
    2. history of previous intraocular surgery;
    3. corneal haze, edema or any condition that can interfere with LFP measurement by means of reduced transparency of the cornea;
    4. preoperative LFP value > 12 ph/ms (as per patient' chart)
    5. pseudoexfoliation lentis;
    6. retinal vascular diseases;
    7. diabetic retinopathy;
    8. any variation of the foveal profile at OCT (including macular edema and epiretinal membranes)
    9. moderate to severe forms of age related macular degeneration
    10. presence of any sign of intraocular inflammation (including cells or flare in the anterior chamber) in either eye (including uveitis);
    11. intraoperative complications during the surgical procedure that may increase postoperative inflammation; this includes, in particular, patients with posterior capsule rupture;
    12. marked intraocular inflammation at postoperative day 1, including keratic precipitates or any form of uveitis;
    13. BCVA ≤ 1/10 in the non study eye
  2. Systemic exclusion criteria:

    1. inflammatory diseases;
    2. any active or chronic/recurrent disease that was uncontrolled and was likely to affect wound healing;
    3. severe blood dyscrasia or bone marrow suppression;
    4. uncontrolled/unstable peptic ulcer disease
    5. any uncontrolled/unstable pulmonary, cardiac, vascular, autoimmune, hepatic, renal, or central nervous system disease;
  3. Known hypersensitivity to bromfenac or to any component of the investigational products, procedural medications, salicylates, or other NSAIDs.
  4. Patients cannot be enrolled in another clinical study concurrently

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03317847

Layout table for location information
Arcispedale Santa Maria Nuova IRCSS - Ophthalmology
Reggio Emilia, RE, Italy, 42123
Sponsors and Collaborators
Arcispedale Santa Maria Nuova-IRCCS
Layout table for investigator information
Principal Investigator: Marco Coassin, MD PhD Santa Maria Nuova Hospital IRCCS
Study Chair: Luigi Fontana Santa Maria Nuova Hospital IRCCS

Layout table for additonal information
Responsible Party: Arcispedale Santa Maria Nuova-IRCCS Identifier: NCT03317847     History of Changes
Other Study ID Numbers: Eudract 2016-004358-14
First Posted: October 23, 2017    Key Record Dates
Last Update Posted: June 18, 2018
Last Verified: June 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Eye Diseases
Ophthalmic Solutions
Capsule Opacification
Pathologic Processes
Lens Diseases
Pharmaceutical Solutions
Dexamethasone acetate
BB 1101
Anti-Inflammatory Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents